Company Overview and News

10
UnitedHealth second quarter medical costs miss estimates, shares slide

15h channelnewsasia
UnitedHealth Group Inc , the largest U.S. health insurer, reported a rise of nearly 28 percent in quarterly profit on Tuesday, driven by growth across its businesses.
ATHTF ANTM CI HUM UNH ANTX

3
UnitedHealth's (UNH) Q2 Earnings Beat, 2018 Guidance Up

16h zacks
UnitedHealth Group Inc.’s (UNH - Free Report) second-quarter 2018 earnings of $3.14 per share surpassed the Zacks Consensus Estimate of $3.03. Also, the reported figure was up 28% year over year.
MOH WCG ANTM UNH

8
How Will Membership Affect UnitedHealth's (UNH) Q2 Earnings?

2018-07-16 zacks
UnitedHealth Group Inc.’s (UNH - Free Report) second-quarter earnings should be partially offset by a decline in enrollment or the number of customers served in the second quarter. Going by the Zacks Consensus Estimate, total medical membership should be 48.89 billion members, down 1.2% year over year.
ATHTF NTRS GTT NTRSP ANTM HUM AET UNH ANTX

4
Centene (CNC) Hits 52 Week High: Is Further Upside Left?

2018-07-06 zacks
On Jul 5, Centene Corp.’s (CNC - Free Report) shares hit a 52 week high of $128.02, ending the day a tad lower at $128.00.
ATHTF CNC MHMI ANTM HUM UNH ANTX

0
Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio

2018-07-03 globenewswire
AUDUBON, Pa., July 03, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today the expansion of its orthopedic trauma product portfolio with two new product offerings, the ANTHEM® Ankle Fracture System and the ANTHEM® Proximal Humerus Fracture System, marking the Trauma division’s fourth and fifth comprehensive product launches over the last 10 months.
ATHTF GMED ANTM ANTX

66
Zacks Industry Outlook Highlights: WellCare, Molina, Humana and Anthem

2018-07-02 zacks
Chicago, IL – July 2, 2018 – Today, Zacks Equity Research discusses Health Insurance, including WellCare Health Plans, Inc. (WCG - Free Report) , Molina Healthcare, Inc. (MOH - Free Report) , Humana Inc. (HUM - Free Report) and Anthem, Inc. (ANTM - Free Report) .
WFC WFCNP WFC.WS WFC.PRL WCG WFC.PRJ ANTM ISRG HUM WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO MOH WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

38
Health Insurance Stock Outlook: Unstoppable Growth Ahead

2018-06-29 zacks
Changing U.S. demography with baby boomers entering retirement age in hordes has pushed up demand for products such as Medicaid and Medicare. This has led to strong membership growth with states turning to private players to manage these plans.
MOH WCG ANTM HUM

93
Zacks.com featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed

2018-06-29 zacks
Chicago, IL – June 29, 2018 - Stocks in this week’s article Anthem Inc. (ANTM - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) , Boston Scientific Corp. (BSX - Free Report) , Grand Canyon Education, Inc. (LOPE - Free Report) and PetMed Express, Inc. (PETS - Free Report) .
ATHTF RYAM LOPE MMSI WLL RL WCG ANTM RYAM.PRA GIII BSX PETS PII ANTX

87
7 GARP Stocks to Scoop Up for Maximum Returns

2018-06-28 zacks
If you’re looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy. It helps an investor gain exposure to stocks that are undervalued and have impressive growth prospects. However, one should not confuse GARP investing with the blend strategy. While the blend strategy promotes investment in both value and growth stocks, GARP investing requires both value and growth features in a single stock.
ATHTF LOPE MMSI BSX PETS ANTM VMW APTV ANTX

64
Community Health Arm to Divest AllianceHealth Deaconess

2018-06-27 zacks
Community Health Systems, Inc. (CYH - Free Report) recently announced that one of its units has signed a definitive agreement to sell 291-bed AllianceHealth Deaconess hospital in Oklahoma City, OK along with other related businesses to a subsidiary of INTEGRIS Health. The transaction is expected to close in the third quarter of 2018, subject to customary regulatory approvals and closing conditions.
CYH RNVAZ RNVA WCG CYHHZ ANTM HUM RNVAW

39
4 Solid Reasons to Retain Anthem (ANTM) in Your Portfolio

2018-06-27 zacks
Estimates for Anthem, Inc. (ANTM - Free Report) have been revised upward over the past 30 days, reflecting analysts’ confidence in the stock. The stock has seen the Zacks Consensus Estimate for 2018 and 2019 earnings being raised 0.60% and 0.59%, respectively. Anthem is poised to gain from a thriving health insurance industry. A strong U.S. economy has enabled the health insurance industry to stand in good stead.
GTS WCG ANTM HUM

132
Sky-High Deductibles Broke the U.S. Health Insurance System - Bloomberg

2018-06-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ATHTF BRK.A CCV.CL CCV CMCSA CCZ ANTM CVS CMCSK ANTX

162
Amazon-Berkshire-JPMorgan Health Venture Takes Aim at Middlemen - Bloomberg

2018-06-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ATHTF BRK.A ANTM CI CVS AET UNH ANTX

43
UnitedHealth's Ratings Upgraded by A.M. Best, Outlook Stable

2018-06-22 zacks
Credit rating giant A.M. Best recently upgraded UnitedHealth Group Incorporated’s (UNH - Free Report) Long-term Issuer Credit Ratings from “a” to “a+” and has also affirmed the Financial Strength Rating (FSR) of A (Excellent) for most UnitedHealthcare insurance subsidiaries. The outlook remains stable. Additionally, the credit rating body has upgraded the Long-Term ICR of the company to “a-” from “bbb+” along with the Long-Term Issue Credit Ratings (Long-Term IR) to “a-” from “bbb+” for the existing senior unsecured notes and its Short-Term Issue Credit Rating (Short-Term IR) to AMB-1 from AMB-2.
WCG ANTM HUM UNH

79
Triple-S Management (GTS) Soared to a 52-Week-High, Time to Cash Out?

2018-06-21 zacks
Have you been paying attention to shares of Triple-S Management (GTS - Free Report) ? Shares have been on the move, with the stock up 14.7% over the past month. GTS hit a new 52-week-high of $41.92 in the previous session. Triple-S Management has gained 67.9% since the start of the year compared to the 2.3% move for the Medical sector and the 13.7% year-to-date return for its peer group.
CECO MS.PRE WCG MS.PRF MS.PRG ANTM HUM MS.PRA MS.PRI AMCX GTS MS.PRK MS BRKS

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ANTM / Anthem, Inc. on message board site Silicon Investor.

ANTM Antennas America
CUSIP: 036752103